Literature DB >> 34859136

A Nucleocapsid-based Transcomplementation Cell Culture System of SARS-CoV-2 to Recapitulate the Complete Viral Life Cycle.

Yanying Yu1, Xiaohui Ju1, Qiang Ding1.   

Abstract

The ongoing COVID-19 pandemic is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). As this virus is classified as a biosafety level-3 (BSL-3) agent, the development of countermeasures and basic research methods is logistically difficult. Recently, using reverse genetics, we developed a BSL-2 cell culture system for production of transcription- and replication-component virus-like-particles (trVLPs) by genetic transcomplementation. The system consists of two parts: SARS-CoV-2 GFP/ΔN genomic RNA, in which the nucleocapsid (N) gene, a critical gene for virion packaging, is replaced by a GFP reporter gene; and a packaging cell line for ectopic expression of N (Caco-2-N). The complete viral life cycle can be recapitulated and confined to Caco-2-N cells, with GFP positivity serving as a surrogate readout for viral infection. In addition, we utilized an intein-mediated protein splicing technique to split the N gene into two independent vectors and generated the Caco-2-Nintein cells as a packaging cell line to further enhance the security of this cell culture model. Altogether, this system provides for a safe and convenient method to produce trVLPs in BSL-2 laboratories. These trVLPs can be modified to incorporate desired mutations, permitting high-throughput screening of antiviral compounds and evaluation of neutralizing antibodies. This protocol describes the details of the trVLP cell culture model to make SARS-CoV-2 research more readily accessible.
Copyright © 2021 The Authors; exclusive licensee Bio-protocol LLC.

Entities:  

Keywords:  BSL-2; Nucleocapsid; Reverse genetics; SARS-CoV-2; Transcomplementation; trVLP

Year:  2021        PMID: 34859136      PMCID: PMC8595423          DOI: 10.21769/BioProtoc.4257

Source DB:  PubMed          Journal:  Bio Protoc        ISSN: 2331-8325


  14 in total

1.  Production and purification of lentiviral vectors.

Authors:  Gustavo Tiscornia; Oded Singer; Inder M Verma
Journal:  Nat Protoc       Date:  2006       Impact factor: 13.491

2.  Measuring HCV infectivity produced in cell culture and in vivo.

Authors:  Brett D Lindenbach
Journal:  Methods Mol Biol       Date:  2009

3.  Drug Evaluation during the Covid-19 Pandemic.

Authors:  Benjamin N Rome; Jerry Avorn
Journal:  N Engl J Med       Date:  2020-04-14       Impact factor: 91.245

Review 4.  Engineering SARS-CoV-2 using a reverse genetic system.

Authors:  Xuping Xie; Kumari G Lokugamage; Xianwen Zhang; Michelle N Vu; Antonio E Muruato; Vineet D Menachery; Pei-Yong Shi
Journal:  Nat Protoc       Date:  2021-01-29       Impact factor: 13.491

5.  A novel coronavirus outbreak of global health concern.

Authors:  Chen Wang; Peter W Horby; Frederick G Hayden; George F Gao
Journal:  Lancet       Date:  2020-01-24       Impact factor: 79.321

6.  Quantification of SARS-CoV-2 neutralizing antibody by a pseudotyped virus-based assay.

Authors:  Jianhui Nie; Qianqian Li; Jiajing Wu; Chenyan Zhao; Huan Hao; Huan Liu; Li Zhang; Lingling Nie; Haiyang Qin; Meng Wang; Qiong Lu; Xiaoyu Li; Qiyu Sun; Junkai Liu; Changfa Fan; Weijin Huang; Miao Xu; Youchun Wang
Journal:  Nat Protoc       Date:  2020-09-25       Impact factor: 13.491

Review 7.  Coronavirus reverse genetic systems: infectious clones and replicons.

Authors:  Fernando Almazán; Isabel Sola; Sonia Zuñiga; Silvia Marquez-Jurado; Lucia Morales; Martina Becares; Luis Enjuanes
Journal:  Virus Res       Date:  2014-06-12       Impact factor: 3.303

8.  SARS-CoV-2 Reverse Genetics Reveals a Variable Infection Gradient in the Respiratory Tract.

Authors:  Yixuan J Hou; Kenichi Okuda; Caitlin E Edwards; David R Martinez; Takanori Asakura; Kenneth H Dinnon; Takafumi Kato; Rhianna E Lee; Boyd L Yount; Teresa M Mascenik; Gang Chen; Kenneth N Olivier; Andrew Ghio; Longping V Tse; Sarah R Leist; Lisa E Gralinski; Alexandra Schäfer; Hong Dang; Rodney Gilmore; Satoko Nakano; Ling Sun; M Leslie Fulcher; Alessandra Livraghi-Butrico; Nathan I Nicely; Mark Cameron; Cheryl Cameron; David J Kelvin; Aravinda de Silva; David M Margolis; Alena Markmann; Luther Bartelt; Ross Zumwalt; Fernando J Martinez; Steven P Salvatore; Alain Borczuk; Purushothama R Tata; Vishwaraj Sontake; Adam Kimple; Ilona Jaspers; Wanda K O'Neal; Scott H Randell; Richard C Boucher; Ralph S Baric
Journal:  Cell       Date:  2020-05-27       Impact factor: 41.582

9.  A bacterial artificial chromosome (BAC)-vectored noninfectious replicon of SARS-CoV-2.

Authors:  Yang Zhang; Wuhui Song; Shuiye Chen; Zhenghong Yuan; Zhigang Yi
Journal:  Antiviral Res       Date:  2020-11-17       Impact factor: 5.970

10.  A trans-complementation system for SARS-CoV-2 recapitulates authentic viral replication without virulence.

Authors:  Xianwen Zhang; Yang Liu; Jianying Liu; Adam L Bailey; Kenneth S Plante; Jessica A Plante; Jing Zou; Hongjie Xia; Nathen E Bopp; Patricia V Aguilar; Ping Ren; Vineet D Menachery; Michael S Diamond; Scott C Weaver; Xuping Xie; Pei-Yong Shi
Journal:  Cell       Date:  2021-02-23       Impact factor: 41.582

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.